z-logo
open-access-imgOpen Access
Acetylcholinesterase inhibitors in treatment-resistant psychotic depression
Author(s) -
Chris Smart,
R. Hamish McAllisterWilliams,
David A. Cousins
Publication year - 2017
Publication title -
therapeutic advances in psychopharmacology
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2045-1261
pISSN - 2045-1253
DOI - 10.1177/2045125317718810
Subject(s) - dementia with lewy bodies , psychology , depression (economics) , schizophrenia (object oriented programming) , psychosis , dementia , psychiatry , tolerability , psychotic depression , psychopathology , medicine , neuroscience , adverse effect , pharmacology , disease , macroeconomics , economics
Dopamine receptor antagonists can be effective in psychotic depression but response is not assured. Visual hallucinations may arise from a dysregulation of brain cholinergic systems and acetylcholinesterase inhibitors (AChEIs) can treat such hallucinations in dementia with Lewy bodies (DLB). AChEIs have been used in schizophrenia with some success but their efficacy and tolerability in psychotic depression is unclear. This striking case illustrates AChEIs specifically targeting multimodal hallucinations in treatment-resistant depression. To our knowledge it is the first case report to do so. It highlights the value of delineating psychopathology when considering novel interventions. This case also shows the idiosyncratic nature of side effects and the importance of pursuing different drugs within class.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom